BREAKING NEW GROUND. CHANGING LIVES.
THE BEST IN CANCER CARE, ACCELERATING DISCOVERY, TRANSLATING TO CURES.

CANCER IS BEING REDEFINED

Breakthroughs in cancer research are leading to new understanding and new treatments to create better outcomes and new hope for people affected by cancer. Peter MacCallum Cancer Centre stands at the forefront of this major transformation.

Peter MacCallum Cancer Centre is a place of discovery in which we fiercely pursue research that breaks new ground in cancer treatment and in doing so, changes lives.

We are among the first to identify and adopt new discoveries, to advocate new innovations in the policy and practice of cancer treatment locally, regionally and globally.

At Peter Mac we never forget why we are here – to get the best outcomes for every individual patient, as we have done for over 60 years.
PETER MACCALLUM CANCER CENTRE HAS A STATE-OF-THE-ART, BILLION-DOLLAR FACILITY AT THE VICTORIAN COMPREHENSIVE CANCER CENTRE (VCCC) BUILDING IN MELBOURNE AUSTRALIA.

Our new home enables us to provide even greater specialised and advanced care for cancer patients.

Peter Mac cares about the total wellbeing of our patients, their families and carers, and our community.

Peter Mac patients also have access to treatment and care closer to their homes through four suburban and regional centres equipped to provide leading-edge radiation therapy services.

Peter Mac’s new home at the VCCC building boasts advanced research facilities and strong collaborative networks. In addition to a more supportive, warm and welcoming environment for patients, our new facility includes:

25,000 m² DEDICATED RESEARCH SPACE
160
OVERNIGHT INPATIENT BEDS

110
SAME DAY BEDS

1
A DEDICATED CLINICAL TRIAL UNIT

8
OPERATING THEATRES

2
PROCEDURE ROOMS

42
BED ICU ACCESS

8
RADIATION THERAPY BUNKERS

6
LINEAR ACCELERATORS

47
SEMINAR AND MEETING SPACES

3
LECTURE THEATRES
AREAS OF FOCUS
These developments are radically reshaping the classification, diagnosis and treatment of cancer, creating new hope for people affected by cancer worldwide.
WE CAN EDUCATE AND TRAIN THE FUTURE GLOBAL LEADERS.

PETER MAC’S CENTRE FOR CLINICAL CANCER GENOMICS IS THE PRE-EMINENT CANCER GENOMICS CENTRE IN AUSTRALIA.

It is now recognised that cancer is a disease of the genes and indeed cancer is the most common genetic disease. Research into the critical genes and their mutations, the discipline of genomics, is essential to inform and develop novel and innovative treatments, improve responses and outcomes for our patients.

Peter Mac’s Centre for Clinical Cancer Genomics is the pre-eminent cancer genomics centre in Australia. Our investments in clinical cancer genomics promote excellence nationally and internationally, and our breakthroughs give our patients the most specialised and advanced diagnosis and treatment.

At the Centre we continually build our expertise and increase the specialised bench-to-bedside translation of research findings for adoption in the clinical setting. Our facilities enable increased access to genomic research for our clinical and research staff, as well as local and international providers and partners.

Peter Mac’s Cancer Centre’s Clinical Cancer Genomics Centre attracts the best talent, so we can train and educate the future global leaders.

Unique across the world, our lab-to-bedside genomics model supports the development of targeted agents and collaborations with pharmaceutical and biotech companies, as well as novel clinical trial design to enable the most effective treatments for our patients.
OUR CLINICAL TRIALS HELP CANCER SURVIVORS AROUND THE WORLD.
THROUGH CLINICAL TRIALS, PETER MAC’S CLINICIAN RESEARCHERS ARE ABLE TO ACCESS, EVALUATE, AND ULTIMATELY ESTABLISH MORE EFFECTIVE, LESS TOXIC, AND MORE INDIVIDUALISED THERAPIES FOR OUR CANCER PATIENTS.

WITH MORE THAN 80 ACTIVE CLINICAL TRIALS AND AROUND 150 IN FOLLOW-UP PHASE, OUR CLINICAL TRIALS PROGRAM LARGELY FOCUSES ON THE ONGOING INNOVATION AND UNMET CLINICAL NEEDS IN MEDICAL ONCOLOGY AND HAEMATOLOGY.

OVER THE COMING YEARS, THE PROGRAM WILL BE EXPANDED TO SUPPORT CLINICAL TRIALS IN ALL DISCIPLINES, AND TO ENABLE INVOLVEMENT AND LEADERSHIP OF CLINICAL TRIALS IN EARLY DETECTION AND PREVENTION, RESULTING IN AN INTEGRATED MODEL.

BY 2020, PETER MAC’S CLINICAL TRIALS PROGRAM WILL INCLUDE A WORLD-LEADING EARLY PHASE CLINICAL TRIALS CAPABILITY THAT IS STRONGLY LINKED TO AUSTRALIAN SCIENCE AND INVESTIGATOR-INITIATED CONCEPTS EMERGING BOTH INTERNALLY AND FROM LABORATORIES WITHIN THE VCCC ALLIANCE.

OUR TUMOUR-STREAM BASED CLINICAL RESEARCH WILL BE FURTHER ENHANCED, AND OUR CLINICAL TRIALS RESEARCH IN CANCER IMMUNOLOGY WILL BE INTERNATIONALLY RECOGNISED.
IMMUNOTHERAPY
NEW WAYS TO EMPOWER A PATIENT’S OWN IMMUNE SYSTEM.

PETER MAC CONTINUES TO CREATE NEW HOPE FOR PEOPLE AFFECTED BY CANCER.

Our researchers have discovered new ways to empower a patient’s own immune system to do what it does naturally — fight disease — with far fewer side effects than conventional cancer treatments.

Peter Mac has the largest and most productive human cancer immunology program in Australia.

With eight laboratories, a large cohort of researchers and students, and prestigious research grants and fellowships, our immunotherapy program makes critical discoveries, including mechanistic insights into cancer immune surveillance, the molecular and cellular functions of killer T cells and human cancer susceptibility related to immune deficiency states.

Peter Mac research on adoptive T cell (CAR T Cell) immunotherapy has been translated into clinical trials of acute myeloid leukemia. This research leads the way in human clinical trials, which results in new drugs and new ways of managing and treating cancer, particularly for those affected by melanoma and blood cancers.

Through significant international partnerships with leading commercial companies Peter Mac continue to create new hope for people affected by cancer. Our drug discovery efforts include a program funded by the Wellcome Trust to develop perforin inhibitors to block rejection of allogenic bone marrow stem cells administered to cancer patients following high dose chemotherapy.

Peter Mac’s long-term excellence in cell and tissue manufacture led to the commercialisation and expansion of this business – Cell Therapies – which in its new location in the VCCC building is now the leading and largest facility of its kind in Australia and the Asia-Pacific region.

Ultimately, Peter Mac’s immunotherapy developments continue to make breakthrough advances for truly personalised medicine in Australia and around the world.
WE ARE LEADERS IN CARE AND RESEARCH DISCOVERY.
AN INTEGRATED APPROACH

WE AIM TO IMPROVE THE PHYSICAL AND EMOTIONAL WELLBEING OF EVERYONE WHO ENTERS PETER MAC.

Peter Mac is a comprehensive cancer centre. We are leaders in care and research discovery but also much more. We provide care across the cancer journey and play a critical role in the development of the health system, in advocacy, in prevention and advancing health policy.

The total wellbeing of patients and our community is of key concern. Preventing cancer and improving the patient experience is a part of our pursuit. The total wellbeing of patient’s and our community is paramount.

As part of this pursuit we are partnering with Maggies in the UK to establish a visionary Wellbeing Centre. It will be a place to relax, to get emotional and practical support and complementary therapies.
Our multifaceted leadership role in melanoma and skin cancer has resulted in significant policy changes, leading clinical research and access to the latest advances in therapeutics for our patients.

We are a recognised global leader in public advocacy efforts to improve skin cancer prevention.

This includes public campaigning on the importance of sun protection – there is no safe way of getting a tan. We also collaborated with partners such as the Cancer Council to achieve legislative changes banning sun beds in Victoria when Peter Mac laboratory research and clinical experience showed that solariums increase the risk of melanoma.

Peter Mac has a large team focused on laboratory based and translational melanoma and skin cancer research. This focus enables Peter Mac to test new novel therapies and run clinical trials – giving our patients access to the latest drugs and therapies and ultimately broad access to the Australian community – changing the lives of thousands of Melanoma sufferers.
NEW TECHNOLOGY ADVANCES AND INNOVATION

With our strong partnerships and collaborative networks we embed a culture of innovation and adopt new technologies and ways of working quickly.

Researchers at Peter Mac have informed 3D printing to simulate complex clinical cases and safely trial how radiation interacts with the body.

We developed an easy to use evidence-based, risk-stratification and decision-making software app that can be applied at the bedside, for all patients undergoing surgery.

We established the first public academic robotic cancer surgery program in Australia and participated in the first worldwide 24 hour live robotic surgery event.

We have worked with the preventative health organisation Pink Hope to develop a ‘know your risk’ tool – the online tool will help individuals determine their risk of developing breast cancer and ovarian cancer based on family health history.

PETER MAC IS AT THE FOREFRONT OF NEW RESEARCH AND TREATMENT TECHNOLOGIES.
With our local and international partners, we provide leadership, fellowships and training programs in this area of advanced surgical technology, focusing on quality of life for those affected by prostate cancer.

Peter Mac is leading research into robotic surgery for prostate cancer and focusing on patient outcomes, time to get home, follow-up, cost effectiveness – improving patient’s quality of life and experience.

We are a leading host for international conferences and we have a large program for teaching and training in robotic surgery.